PT3866767T - Composição farmacêutica para administração oral que inclui um derivado de aminopirimidina ou o seu sal - Google Patents

Composição farmacêutica para administração oral que inclui um derivado de aminopirimidina ou o seu sal

Info

Publication number
PT3866767T
PT3866767T PT198724270T PT19872427T PT3866767T PT 3866767 T PT3866767 T PT 3866767T PT 198724270 T PT198724270 T PT 198724270T PT 19872427 T PT19872427 T PT 19872427T PT 3866767 T PT3866767 T PT 3866767T
Authority
PT
Portugal
Prior art keywords
salt
pharmaceutical composition
oral administration
aminopyrimidine derivative
aminopyrimidine
Prior art date
Application number
PT198724270T
Other languages
English (en)
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of PT3866767T publication Critical patent/PT3866767T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT198724270T 2018-10-18 2019-10-17 Composição farmacêutica para administração oral que inclui um derivado de aminopirimidina ou o seu sal PT3866767T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180124171A KR20200043618A (ko) 2018-10-18 2018-10-18 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Publications (1)

Publication Number Publication Date
PT3866767T true PT3866767T (pt) 2024-01-18

Family

ID=70282933

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198724270T PT3866767T (pt) 2018-10-18 2019-10-17 Composição farmacêutica para administração oral que inclui um derivado de aminopirimidina ou o seu sal

Country Status (29)

Country Link
US (1) US20210322428A1 (pt)
EP (2) EP3866767B1 (pt)
JP (2) JP7369769B2 (pt)
KR (2) KR20200043618A (pt)
CN (1) CN113015521A (pt)
AR (1) AR117655A1 (pt)
AU (1) AU2019360446A1 (pt)
BR (1) BR112021007061A2 (pt)
CA (1) CA3116652A1 (pt)
DK (1) DK3866767T3 (pt)
EA (1) EA202191061A1 (pt)
ES (1) ES2968966T3 (pt)
FI (1) FI3866767T3 (pt)
HR (1) HRP20231670T1 (pt)
HU (1) HUE065389T2 (pt)
IL (1) IL282163A (pt)
LT (1) LT3866767T (pt)
MA (1) MA53927B1 (pt)
MD (1) MD3866767T2 (pt)
MX (2) MX2021004457A (pt)
PE (1) PE20211818A1 (pt)
PH (1) PH12021550687A1 (pt)
PL (1) PL3866767T3 (pt)
PT (1) PT3866767T (pt)
RS (1) RS65012B1 (pt)
SG (1) SG11202103057RA (pt)
SI (1) SI3866767T1 (pt)
TW (1) TWI831848B (pt)
WO (1) WO2020079637A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103000A3 (en) * 1998-07-20 2002-08-28 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form and process for their preparation
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
WO2008057266A2 (en) 2006-10-27 2008-05-15 Fmc Corporation Dry granulation binders, products, and use thereof
ES2359377T3 (es) * 2006-10-27 2011-05-23 Fmc Corporation Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
US11453646B2 (en) * 2011-07-27 2022-09-27 Cornell University Methods for RNA detection and quantification
US9884042B2 (en) 2011-09-14 2018-02-06 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
KR101560994B1 (ko) 2011-11-29 2015-10-15 길리어드 파마셋 엘엘씨 간염 c 바이러스 치료를 위한 조성물 및 방법
US9539098B2 (en) * 2013-04-23 2017-01-10 Rev Ortho Llc System for modular hip resurfacing
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
HUE054848T2 (hu) 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
SG10202010389TA (en) 2014-12-16 2020-11-27 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR20180008511A (ko) 2015-05-22 2018-01-24 노파르티스 아게 제약 조성물
WO2017061621A1 (ja) 2015-10-07 2017-04-13 協和発酵キリン株式会社 アリールアルキルアミン化合物含有医薬組成物
RU2745195C2 (ru) 2016-04-07 2021-03-22 Кемосентрикс, Инк. Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物

Also Published As

Publication number Publication date
PH12021550687A1 (en) 2022-02-14
PL3866767T3 (pl) 2024-04-02
CN113015521A (zh) 2021-06-22
PE20211818A1 (es) 2021-09-14
MX2023014946A (es) 2024-02-20
JP2022504943A (ja) 2022-01-13
RS65012B1 (sr) 2024-01-31
HUE065389T2 (hu) 2024-05-28
US20210322428A1 (en) 2021-10-21
EP3866767A4 (en) 2022-07-20
TWI831848B (zh) 2024-02-11
FI3866767T3 (fi) 2024-01-30
MA53927A (fr) 2021-09-15
SI3866767T1 (sl) 2024-02-29
WO2020079637A9 (en) 2020-07-23
MX2021004457A (es) 2021-07-07
CA3116652A1 (en) 2020-04-23
LT3866767T (lt) 2023-12-27
TW202034903A (zh) 2020-10-01
EA202191061A1 (ru) 2021-07-09
KR20200043618A (ko) 2020-04-28
MA53927B1 (fr) 2023-12-29
EP4306113A3 (en) 2024-02-14
SG11202103057RA (en) 2021-05-28
EP3866767A1 (en) 2021-08-25
KR20210061457A (ko) 2021-05-27
AU2019360446A1 (en) 2021-04-22
ES2968966T3 (es) 2024-05-14
BR112021007061A2 (pt) 2021-07-20
WO2020079637A1 (en) 2020-04-23
AR117655A1 (es) 2021-08-25
JP2024016052A (ja) 2024-02-06
HRP20231670T1 (hr) 2024-03-15
EP4306113A2 (en) 2024-01-17
MD3866767T2 (ro) 2024-06-30
IL282163A (en) 2021-05-31
EP3866767B1 (en) 2023-11-29
DK3866767T3 (da) 2024-01-29
JP7369769B2 (ja) 2023-10-26

Similar Documents

Publication Publication Date Title
IL282163A (en) A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or its salt
IL270812A (en) Solid compositions for oral drug administration
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
EP3851121A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING A HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY
IL290469A (en) Oral pharmaceutical preparation
HK1245646A1 (zh) 口服給藥用醫藥組合物
GB202103764D0 (en) Pharmaceutical suspension for oral dosage
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
HK1243351A1 (zh) 一種含有吡啶並嘧啶類衍生物或其可藥用鹽的藥物組合物
SG11202101547WA (en) Pharmaceutical composition for oral administration
HUE062682T2 (hu) Ibuprofén tartalmú orális gyógyszerészeti készítmény
SI3778609T1 (sl) Derivati penama ali njenih soli, farmacevtski sestavki in njihova uporaba
EP3650024A4 (en) PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION
GB2569616B (en) Sustained release oral pharmaceutical compositions of dicycloverine
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof